Oxford Biomedica’s (OXB) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Oxford Biomedica (LON:OXB) in a research report released on Tuesday morning, MarketBeat.com reports. The firm currently has a GBX 740 ($9.41) price objective on the biopharmaceutical company’s stock.

Separately, Numis Securities reissued a hold rating and set a GBX 180 ($2.29) price target on shares of Oxford Biomedica in a research report on Wednesday, March 20th.

Oxford Biomedica Stock Down 2.2 %

Oxford Biomedica stock opened at GBX 327 ($4.16) on Tuesday. Oxford Biomedica has a twelve month low of GBX 164.29 ($2.09) and a twelve month high of GBX 474.50 ($6.03). The stock has a 50 day moving average of GBX 247.59 and a two-hundred day moving average of GBX 209.41. The company has a current ratio of 3.32, a quick ratio of 1.67 and a debt-to-equity ratio of 57.10. The stock has a market capitalization of £327 million, a price-to-earnings ratio of -510.94 and a beta of 1.03.

About Oxford Biomedica

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.